Sanctions ​And Export Control Risks For Health Care Cos.

Law360, New York (May 19, 2017, 3:49 PM EDT) -- Over the past 15 years, pharmaceutical manufacturers, medical device companies and other participants in the health care industry have been regular targets of U.S. Foreign Corrupt Practices Act (“FCPA”) enforcement actions brought by the U.S. government. FCPA cases levied against health care companies have commanded significant attention, and many companies have responded by implementing robust anti-corruption compliance programs consisting of policies and procedures, employee training, risk-based due diligence and proactive compliance testing and monitoring.

Recent settlements suggest that a new trend may be emerging: the U.S....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.